Emerald secures $2M to rewire diagnostics with AI
US-based healthtech startup Emerald has closed a $2 million pre-seed round to build a platform that tightly integrates blood testing, AI diagnostics and everyday medical care. The company aims to shorten the gap between lab results and clinical decisions by turning raw data into real-time, actionable insights for clinicians and patients.
Blending blood data, algorithms and clinical workflows
Emerald is developing software that ingests standard laboratory blood panels and transforms them into structured, longitudinal health profiles. Using proprietary AI algorithms, the platform flags early signs of disease risk, suggests follow-up tests and surfaces guideline-based treatment options directly inside existing electronic health record (EHR) workflows.
Rather than replacing doctors, the startup positions its technology as a decision-support layer. By automating pattern recognition across thousands of biomarkers and historical test results, Emerald wants to reduce diagnostic delays, cut unnecessary repeat testing and give clinicians a clearer picture of patient trajectories over time.
Targeting primary care and chronic disease management
The initial focus is on primary care and chronic disease management, where routine blood work is common but often underutilised. The company believes that better interpretation of standard tests can improve outcomes in areas such as cardiovascular risk, metabolic disorders and autoimmune conditions without requiring expensive new hardware.
By offering dashboards for both clinicians and patients, Emerald also aims to support personalised care plans, medication adjustments and lifestyle interventions based on continuously updated lab data.
Use of funds and regulatory path
The pre-seed funding will be used to expand the engineering and clinical science teams, validate the platform with partner clinics and advance the company’s regulatory and data security frameworks. A key priority is ensuring that the AI models meet stringent standards for accuracy, bias mitigation and patient privacy, positioning the product for broader deployment in hospitals, outpatient networks and digital health programs.
With investors backing its vision of lab-informed, AI-guided care, Emerald is entering a crowded but rapidly growing healthtech market that is racing to make diagnostics faster, more precise and more accessible.